Dr. Wenhua Yu (Jocelyn) is a seasoned intellectual property (IP) attorney focusing in the life sciences industry. She assists clients — ranging from biotech start-ups to multinational pharmaceutical companies — in maximizing IP protection and leveraging IP rights to strengthen business strategies and transactions. Jocelyn's experience spans global patent strategy and portfolio development, IP due diligence, and partnership negotiations.
Jocelyn focuses on crafting tailored IP and patent strategies, working closely with scientific teams to guide product design from the IP perspective to manage future risks and avoid third-party patent barriers. Her deep technical knowledge covers immunotherapies, gene and cell therapies, vaccines, small-molecule drugs, conjugated drugs, and drug manufacturing and delivery technologies.
Jocelyn also advises clients on technology transaction and partnership strategies, including structuring, negotiating, and preparing licensing and collaboration agreements for biotech and pharmaceutical companies. She counsels clients on post-execution relationship management, investigation, and resolution of IP-related disputes. Jocelyn has represented clients in cross-border transactions between the United States, European, and Asian markets.
Jocelyn is a member of the Board of Directors for SoCal Association for Biomedical and Pharmaceutical Advancements (SABPA). Jocelyn co-chairs the IP & Patent Law Committee for Biocom California. She was recently named a San Diego Business Journal "Leader of Influence in Law."
担当案件
- October 28, 2026
Beyond the Patent Group: Identifying and Managing IP Issues Across Legal Functions (CLE panel with PALSD in- house counsel committee) - June 21, 2026
Panel Discussion: Commercialization Trends - MNCs & China Biopharma (BIOCHINA Global Forum@USA) - April 11, 2026
Accelerating Oncology Drug Development by Leveraging US-China Collaboration (Panel discussion with American Healthcare Executive Association with panelists: David Lee, Partner of Jones Day; Alex Cogdill Head of Strategic Initiatives Global Business Development Daiichi Sankyo; Astrid Ruefli-Brasse, Vice President Tumor Biology at Pfizer; Kim Watanabe, Thermo Fisher Scientific; Suguna Rachakonda, VP Business Development) - January 11, 2026
Global Strategy & MNC Outlook: How Leading Pharma Integrates Regional Innovation and Partnership Models (Panel discussion @ Global Biopharma Leadership Forum with panelists: Echo Hindle-Yang Founder & CEO MSQ Ventures; Alex Cogdill Head of Strategic Initiatives Global Business Development Daiichi Sankyo; Dan Zheng Head of Regional Innovation and Partnerships Takeda, Ying Niu China Search and Evaluation Lead Pfizer; Mike Patten Chief Strategy Officer Harbour Biomed; Nikhil Mutyal Head of Search and Evaluation Respiratory & Immunology AstraZeneca) - October 27, 2022
Practical Considerations in Continuation/Divisional Patent Application Practice - September 28, 2022
Key topics for negotiation in Cross-the-Border Out-Licensing of Pharmaceutical Assets and Case Studies (Presentation in Mandarin) - January 25, 2022
Key Topics For Negotiation in Life Science Licensing Transactions - November 7, 2018
Licensing Fundamentals for Business Executives and Startups
- Northwestern University (J.D. 2016); Pennsylvania State University (Ph.D. in Genetics 2010); Wuhan University, China (B.S. in Pharmaceutical Sciences 2004)
- California and registered to practice before the U.S. Patent and Trademark Office
San Diego Business Journal: Leaders of Influence in Law (2025)
Best Lawyers: Ones to Watch in America (2024-2026)
- Mandarin